Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Interest Expenses (2020 - 2025)

Mirum Pharmaceuticals has reported Interest Expenses over the past 6 years, most recently at $3.6 million for Q4 2025.

  • Quarterly results put Interest Expenses at $3.6 million for Q4 2025, up 0.53% from a year ago — trailing twelve months through Dec 2025 was $14.4 million (up 0.55% YoY), and the annual figure for FY2025 was $14.4 million, up 0.55%.
  • Interest Expenses for Q4 2025 was $3.6 million at Mirum Pharmaceuticals, roughly flat from $3.6 million in the prior quarter.
  • Over the last five years, Interest Expenses for MIRM hit a ceiling of $5.7 million in Q3 2021 and a floor of $3.4 million in Q1 2021.
  • Median Interest Expenses over the past 5 years was $3.6 million (2025), compared with a mean of $3.9 million.
  • Biggest five-year swings in Interest Expenses: skyrocketed 1024.18% in 2021 and later decreased 29.93% in 2022.
  • Mirum Pharmaceuticals' Interest Expenses stood at $3.8 million in 2021, then increased by 15.75% to $4.4 million in 2022, then dropped by 18.26% to $3.6 million in 2023, then rose by 0.45% to $3.6 million in 2024, then increased by 0.53% to $3.6 million in 2025.
  • The last three reported values for Interest Expenses were $3.6 million (Q4 2025), $3.6 million (Q3 2025), and $3.6 million (Q2 2025) per Business Quant data.